Arbutus Biopharma Corporation
Organization details
- Legal name
- Arbutus Biopharma Corporation
- Former names
- Tekmira Pharmaceuticals Corp
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- British Columbia, Canada
- Headquarters city
- Warminster
- Headquarters state / province
- Pennsylvania
- Headquarters country
- Canada
- Fiscal year end
- December
- Ticker symbol
- ABUS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001447028
- EIN
- 98-0597776
- Wikidata ID
- Q17747021
Board of directors
-
Anuj Hasija · DirectorSince 2025
-
Daniel D. Burgess · DirectorSince 2023
-
Frank Torti · DirectorSince 2023
-
James R. Meyers · DirectorSince 2023
-
Joseph E. Bishop · DirectorSince 2025
-
Keith S. Manchester · DirectorSince 2023
-
Lindsay Androski · Director · President and CEOSince 2025
-
Matthew Gline · DirectorSince 2025
-
Melissa Rewolinski · DirectorSince 2023
-
Michael J. McElhaugh · Director · Interim President & CEOSince 2024
-
Richard C. Henriques Jr. · DirectorSince 2023
-
Robert A. Beardsley · DirectorSince 2025
-
Roger Sawhney · DirectorSince 2025
-
William H. Collier · Director · President and CEOSince 2023
Chief executives
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
128.2% a year in revenue
20% of the scoring weight is on file. Figures cover December 2024 – December 2025.
Director election results
Annual meeting of May 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
86.5%
-
93.4%
-
93.8%
-
94.5%
-
95.1%
Board connections
7 of this board's directors also sit on 8 other boards. 8 are in the same sector.
-
Roivant Sciences Ltd. Same sectorvia Keith S. Manchester and Matthew Gline
-
Actuate Therapeutics Inc. Same sectorvia Roger Sawhney
-
Adlai Nortye Group Ltd. Same sectorvia Roger Sawhney
-
Cabaletta Bio Inc. Same sectorvia Richard C. Henriques Jr.
-
CytomX Therapeutics Inc. Same sectorvia James R. Meyers
-
Eloxx Pharmaceuticals Inc. Same sectorvia Lindsay Androski
-
Immunovant Inc. Same sectorvia Frank Torti
-
Vera Therapeutics Inc. Same sectorvia James R. Meyers
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 1, 2026 | Roivant Sciences Ltd. Director, 10% owner | Sold back to the company | −8,967,383 | $5.00 | $44,836,915 |
| Oct 1, 2026 | Lindsay Androski Director, Officer (President and CEO) | Sold back to the company | −24,655 | $5.00 | $123,275 |
| Oct 1, 2026 | Roger Sawhney Director | Sold back to the company | −17,142 | $5.00 | $85,710 |
| Oct 1, 2026 | Nguyen Tuan Officer (Chief Financial Officer) | Sold back to the company | −48,081 | $5.00 | $240,405 |
| Oct 1, 2026 | Robert A. Beardsley Director | Sold back to the company | −17,948 | $5.00 | $89,740 |
| Sep 18, 2026 | Lindsay Androski Director, Officer (President and CEO) | Option exercise | +116,408 | $3.20 | $372,506 |
| Sep 18, 2026 | Robert A. Beardsley Director | Option exercise | +52,533 | $3.20 | $168,106 |
| Sep 18, 2026 | Roger Sawhney Director | Option exercise | +52,533 | $3.34 | $175,460 |
| Sep 18, 2026 | Nguyen Tuan Officer (Chief Financial Officer) | Option exercise | +265,625 | $3.49 | $927,031 |
| Sep 18, 2026 | Lindsay Androski Director, Officer (President and CEO) | Option exercise | +10,456 | $4.39 | $45,902 |
| Sep 18, 2026 | Robert A. Beardsley Director | Option exercise | +78,800 | $4.24 | $334,112 |
| Sep 18, 2026 | Roger Sawhney Director | Option exercise | +78,800 | $4.24 | $334,112 |
| Sep 18, 2026 | Nguyen Tuan Officer (Chief Financial Officer) | Option exercise | +27,475 | $4.39 | $120,615 |
| Sep 18, 2026 | Lindsay Androski Director, Officer (President and CEO) | Shares withheld for tax | −82,527 | $5.07 | $418,412 |
| Sep 18, 2026 | Robert A. Beardsley Director | Shares withheld for tax | −99,057 | $5.07 | $502,219 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Arbutus Biopharma Corporation
Who is the CEO of Arbutus Biopharma Corporation?
Lindsay Androski has been Arbutus Biopharma Corporation's President and CEO since February 2025.
How many directors are on Arbutus Biopharma Corporation's board?
Arbutus Biopharma Corporation's board has 14 directors: Anuj Hasija, Daniel D. Burgess, Frank Torti, James R. Meyers, Joseph E. Bishop, Keith S. Manchester, Lindsay Androski, Matthew Gline, Melissa Rewolinski, Michael J. McElhaugh and 4 others.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="arbutus-biopharma-corporation"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.